Mesenchymal stem cell therapy shows promise for treating MS, but more research is needed on long-term safety and efficacy, a review found.

Tyruko, the first biosimilar of Tysabri, is now available in the U.S., providing a lower-cost treatment option for adults ...

Sandoz’s Tyruko (natalizumab), the only FDA approved natalizumab biosimilar for adults with relapsing multiple sclerosis and Crohn’s disease, is now available by prescription in the United States ...

OMAHA, Neb. (WOWT/Gray News) - A Nebraska woman has become the first patient in the world to undergo a groundbreaking new treatment for multiple sclerosis. Seven years ago, Jan Janisch-Hanzlik began ...

Researchers in the Rady Faculty of Health Sciences are exploring whether a person's genetic risk for depression can help ...

CMSC 2023 Multiple Changes in NMOSD Treatment Tied to Poorer Outcomes Multiple treatment transitions in patients with NMOSD are associated with increased neurological harm, including increased relapse ...

An insurance company repeatedly denied a Wisconsin woman coverage for a medication her doctor prescribed to treat her ...